Abstract 2137P
Background
Performance ECOG status and staging are described as prognostic factors in oncologic outpatients while nutritional assessment can impact survival in both outpatients and inpatients. The aim of this study was to describe the Charslon Comorbidity Index (CCI), the nutritional status, the impact of opioid therapy and psycho-oncology and palliative care unit intervention for hospitalized cancer patients (pts).
Methods
A prospective multicentric study of pts hospitalized between January 2020 February 2022 at Vall d’Hebron and Sant Pau Hospitals [Plantology database] in Spain. Demographic and clinical variables such as CCI, laboratory results and nutritional status were collected at admission. Prognostic Nutritional Index (PNI) was calculated at admission. Quality of life (QoL) was collected through the EORTC-QLQ30 v.3 questionnaire. Statistical analysis was performed with SPSS v.29 (Log rank, Chi-square, Student’s t-test were used).
Results
A total of 1.431 patients (median age 66 years, 53.2% males) were included with a median of 9 days hospitalized. With a follow-up of 15 months, the median survival was 4.67 months after admission. Most pts (91.6%) had severe comorbidity (CCI ≥ 5 points) related to a lower survival (4.5 vs 12.8 months, p<0.001). A positive chair stand test for sarcopenia (12.2%) was associated with reduced survival (3.5 vs 9.1 months, p<0.001). Pts with hypoalbuminemia (65.3%) presented lower survival (3.5 vs 8.4 months, p<0.001). In addition, the PNI stratified 59.5% pts with serious malnutrition (PNI <40) linked to reduced survival (3.6 vs 7.9 months, p<0.001). Regarding supportive care, pts under opioid therapy (39.6%) had a higher QoL (mean EORTC QLQ-30 score of 73.4 vs 64.3, p<0.001). Palliative care team assessment and psycho-oncology intervention positively impacted in pts QoL (EORTC QLQ-30 of 74 vs 67.3, p<0.001, and 74.3 vs 65.2, p<0.001, respectively).
Conclusions
In hospitalized cancer pts, severe comorbidity, malnutrition and sarcopenia were associated with a reduced survival. Opioid therapy and psycho-oncological and palliative care unit intervention had a positive impact on the QoL of pts. Early supportive care interventions are key to improve symptomatology and preserve QoL of hospitalized cancer pts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
VHIO.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2194P - Prospective observational study of physical activity measurement using wearable device as an alternative to ECOG PS in patients with advanced lung cancer
Presenter: Kentaro Ito
Session: Poster session 07
Resources:
Abstract
2195P - Targeted gene editing with CRISPR for the treatment of pleural mesothelioma
Presenter: Rodrigo Dominic Cerqueda
Session: Poster session 07
2196P - PET-CT detects response to treatment with ipilimumab and nivolumab in malignant mesothelioma far better than CT
Presenter: Daniel C. Christoph
Session: Poster session 07
2197P - Prognostic value of 18F-FDG-PET for patients with malignant pleural mesothelioma treated with double immunotherapy
Presenter: Solfrid Thunold
Session: Poster session 07
2198P - Clinicopathologic characteristics and outcomes to immune checkpoint inhibitor therapy in patients with HER2-altered metastatic non-small cell lung cancer
Presenter: Maisam Makarem
Session: Poster session 07
2199P - Immunohistochemical identification of clinical subtypes and potential therapeutic vulnerabilities of lung carcinoids based on multi-omic analysis
Presenter: Jules Derks
Session: Poster session 07
2200P - Spatiotemporal distribution of mediastinal neoplasms: A multi-center, hospital-based, systematic analysis
Presenter: Yu Jiang
Session: Poster session 07
2201P - Malignant pleural mesothelioma (MPM)-specific DNA methylation patterns in patients using liquid biopsies
Presenter: Sabine Schmid
Session: Poster session 07
2202P - Large cell neuroendocrine carcinoma (LCNEC) subtyping based on NEUROD1, ASCL1, POU2F3 and YAP1 expression
Presenter: Frank Heijboer
Session: Poster session 07
2203P - Uncovering prognostic transcriptomic differences in epithelioid malignant pleural mesothelioma
Presenter: Mario Occhipinti
Session: Poster session 07